Skip to main content
. 2019 Dec 26;47(3):665–673. doi: 10.1007/s00259-019-04635-7

Fig. 1.

Fig. 1

Patient-based changes in SUVmax after the administration of ADT (degarelix). Orange line, prostate lesions; blue line, lymph node metastases; green lines, bone metastases; dotted vertical line, initiation of androgen deprivation therapy (ADT)